GlobeNewswire: Bellicum Pharmaceuticals, Inc. Contains the last 10 of 137 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T09:31:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/03/14/2627212/0/en/Bellicum-Discontinues-Phase-1-2-Trials-and-Initiates-Evaluation-of-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=31338Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives2023-03-14T20:30:00Z<![CDATA[HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid.]]>https://www.globenewswire.com/news-release/2023/02/16/2609615/0/en/Bellicum-Presents-Early-Phase-1-Results-for-BPX-601-in-Prostate-Cancer-at-ASCO-GU-Cancers-Symposium.html?f=22&fvtc=4&fvtv=31338Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium2023-02-16T12:30:00Z<![CDATA[Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients]]>https://www.globenewswire.com/news-release/2023/01/31/2599032/0/en/CORRECTION-Bellicum-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31338CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-01-31T23:43:51Z<![CDATA[HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows:]]>https://www.globenewswire.com/news-release/2023/01/31/2598995/0/en/Bellicum-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31338Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2023-01-31T21:36:43Z<![CDATA[HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of January 31, 2023. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2023/01/19/2591682/0/en/Bellicum-Pharmaceuticals-to-Present-Early-Phase-1-Results-for-BPX-601-in-Prostate-Cancer-at-ASCO-2023-Genitourinary-Cancers-Symposium.html?f=22&fvtc=4&fvtv=31338Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium2023-01-19T12:30:00Z<![CDATA[HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T® product candidate, has been accepted for poster presentation at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU). The meeting is being held February 16-18, 2023 in San Francisco and virtually. The ongoing trial is being conducted in patients with metastatic castration-resistant prostate cancer.]]>https://www.globenewswire.com/news-release/2022/12/11/2571433/0/en/Bellicum-Announces-Presentation-by-UNC-at-ASH-2022-on-Potential-Abrogation-of-iC9-CAR-T-Cell-Toxicities-with-Rimiducid.html?f=22&fvtc=4&fvtv=31338Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid2022-12-11T15:00:00Z<![CDATA[HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger) team at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition being held in New Orleans December 10-13, 2022. The presentation, scheduled for today at 6 p.m. CT, will provide data on four patients who received rimiducid to activate the CaspaCIDe® safety switch in an investigator sponsored trial.]]>https://www.globenewswire.com/news-release/2022/11/10/2553805/0/en/Bellicum-Reports-Third-Quarter-2022-Financial-Results-and-Provides-Operational-Update.html?f=22&fvtc=4&fvtv=31338Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update 2022-11-10T21:05:00Z<![CDATA[HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2022 and provided an operational update.]]>https://www.globenewswire.com/news-release/2022/10/31/2545045/0/en/Bellicum-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31338Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2022-10-31T21:49:19Z<![CDATA[HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 45,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 31, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).]]>https://www.globenewswire.com/news-release/2022/10/04/2527684/0/en/Bellicum-Pharmaceuticals-to-Participate-in-the-2022-Cell-Gene-Meeting-on-the-Mesa.html?f=22&fvtc=4&fvtv=31338Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa2022-10-04T11:30:00Z<![CDATA[HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick Fair, President and CEO, will present at the annual Cell & Gene Meeting on the Mesa to be held October 11-13 in Carlsbad, CA and livestreamed globally.]]>https://www.globenewswire.com/news-release/2022/10/03/2527307/0/en/Bellicum-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=31338Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2022-10-03T20:05:00Z<![CDATA[HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 70,000 stock options. The Compensation Committee of the Board of Directors approved the grants with an effective date of September 30, 2022. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).]]>